2. Breaking Barriers in Sexual Health: Dicot Pharma’s LIB-01 and the Future of ED Treatment

This episode of BioBiz Buzz spotlights the rapidly growing global markets for erectile dysfunction (ED) and premature ejaculation (PE), conditions impacting over 500 million men worldwide. 

Your host Mike Ward interviews Elin Trampe, CEO of Dicot Pharma, who discusses the company’s innovative drug candidate, LIB-01. 

Unlike conventional therapies, LIB-01 introduces a novel mechanism of action and offers a significantly longer efficacy window, 28 days after a brief 3-day dosing according to exploratory data in the phase 1 trial, potentially transforming the standard of care for both ED and PE. 

Trampe shares insights on the drug’s clinical progress, the company’s strategic partnerships, and efforts to reduce the stigma surrounding sexual health. 

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer

● LinkedIn